Aldeyra Therapeutics, Inc.
NASDAQ:ALDXBiotechnology
+$0.06 today
- Market cap
- $54.28M
- Beta
- 1.19
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$0.45
Volume 1.45M
Average 2.13M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
Intrinsic Alpha fair value
Locked
Current Price
$0.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Alto Neuroscience, Inc. NYSE:ANRO | $929.64M | $26.49 | Not rated | -9.8 | +68.88% |
Candel Therapeutics, Inc. NASDAQ:CADL | $807.44M | $11.02 | Not rated | -9.2 | +16.88% |
Silence Therapeutics plc NASDAQ:SLN | $528.08M | $11.18 | Not rated | -3.9 | +193.33% |
Contineum Therapeutics, Inc. Class A Common Stock NASDAQ:CTNM | $472.52M | $12.56 | Not rated | -7.5 | -17.03% |
Kyverna Therapeutics, Inc. NASDAQ:KYTX | $414.02M | $6.81 | Not rated | -3.1 | -39.97% |
Amarin Corporation plc NASDAQ:AMRN | $273.01M | $13.20 | Not rated | -9.9 | -32.56% |
AC Immune S.A. NASDAQ:ACIU | $256.47M | $2.52 | Not rated | -2.9 | -30.82% |
Cellectis S.A. NASDAQ:CLLS | $147.61M | $1.47 | Not rated | -4.6 | -74.21% |
Genelux Corporation NASDAQ:GNLX | $111.20M | $2.48 | Not rated | -3.0 | -60.47% |
Mereo BioPharma Group plc NASDAQ:MREO | $59.06M | $0.37 | Not rated | -1.4 | -82.42% |
Continue the stock analysis
Jump to another research area for this company.